Short answer
ACCENDRA HEALTH INC/VA/ (ACH) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $613M with net income of −$89M.
Q2 2026 key financials · XBRL
- Revenue
- $613M
- −2.3% QoQ
- Net income
- −$89M
- +89.8% YoY · −1277.1% QoQ
- Operating margin
- -5.7%
- EPS (diluted)
- −$1.17
- +89.6% YoY · −1362.5% QoQ
Source: XBRL data from the ACCENDRA HEALTH INC/VA/ (ACH) Q2 2026 10-Q on SEC EDGAR. USD.
ACCENDRA HEALTH INC/VA/ Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $613.2M, down 10.1% YoY from $681.9M, driven by commercial payor contract termination
- Cost margin 57.0% vs 52.4% YoY; SG&A margin 39.7% vs 39.3%
- Best segment Urology, revenue $31.3M, up 9.1%; worst Other, $47.7M, down 34.1%
- Cash $7.7M vs $282.0M at December 31; six-month operating cash flow $(76.1)M
- Free cash flow $(25.1)M vs $15.2M; $43.8M patient-service equipment capital expenditures
Risk Factors
- No material changes to 10-K risk factors through June 30, 2026
- Debt risk: New 9.000% senior secured notes due 2032
- Debt risk: New 9.750% senior secured notes due 2033
- Liquidity risk: $100 million repurchase authorization, with $89.860 million remaining
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ACCENDRA HEALTH INC/VA/ quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.